[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chung Shan Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":494},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,49,76,99,123,151,176,205,227,250,284,307,334,364,397,422,453,473],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100643902","development--validation-of-a-life-balance-program-for-parents-of-preschoolers-a-pilot-study-100643902",false,"NCT07669896","Development & Validation of a Life Balance Program for Parents of Preschoolers: A Pilot Study","A Wonderful Life is Not a Dream-A Pilot Study on the Development and Effectiveness Validation of the Life Balance Improvement Program for Parents of Preschool Children","Inclusion Criteria:\n\n* Parents aged 18 to 65 years who have at least one preschool child aged 0 to 6 years\n* The primary caregiver of the child\n* Self-perceived poor life balance or high parenting stress\n* Self-perceived depressive or anxiety symptoms, with at least mild depression as indicated by the Beck Depression Inventory, or at least mild anxiety as indicated by the Beck Anxiety Inventory\n* Able to communicate in Mandarin Chinese and comply with the study procedures, including interviews and self-administered questionnaires\n\nExclusion Criteria:\n\n* The child has been diagnosed by a physician with a major physical illness, mental illness, or neurodevelopmental disorder\n* The parent has been diagnosed by a physician with a major physical or mental illness requiring long-term treatment",true,"ALL","18 Years","65 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to examine the relationships among life balance, parenting stress, and mental health in parents of preschool children, and to develop an individualized life balance promotion program for this population. Parents of preschool children will be recruited to support program development and to evaluate its feasibility and effectiveness.",[28,29,30],"Parenting Stress","Mental Health","Occupational Balance",[32,30,28,33,34,35,36],"Preschool Parents","Depression","Anxiety","Group Intervention","Individualized intervention","NOT_YET_RECRUITING","2026-06-21",{"date":40,"type":41},"2026-06-25","ACTUAL",{"date":43,"type":22},"2026-07",{"date":45,"type":22},"2027-12",{"name":47,"class":48},"Chung Shan Medical University","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100641633","hf-rtms-primed-balance-training-on-corticomotor-excitability-balance-and-gait-in-parkinsons-100641633","NCT07653256","HF-rTMS Primed Balance Training on Corticomotor Excitability, Balance, and Gait in Parkinson's","Effects of High-frequency Repetitive Transcranial Magnetic Stimulation-primed Balance Training on Corticomotor Excitability, Balance, and Gait Performance in Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosed with idiopathic PD\n* Aged between 40-80 years\n* Stable on antiparkinsonian medication ( \\> 3 months)\n* H\\&Y I-III\n* Able to walk continuously for at least 10 minutes\n* The ability to follow commands and instructions\n\nExclusion Criteria:\n\n* Neurological diseases other than PD\n* Severe musculoskeletal, cardiopulmonary disorders\n* MMSE \\\u003C 24\n* Contraindications for TMS\n* Have undergone or are scheduled to undergo neurological surgery during the study participation period","40 Years","80 Years",{"count":59,"type":22},20,[25],"This study aims to investigate the effects of repeated transcranial magnetic stimulation combined with modified otago exercise program balance training intervention on motor cortex excitability, balance, and gait performance in patients with Parkinson's disease.",[63,64,65,66,67],"Parkinson's Disease","Corticomotor Excitability","Balance Control","Gait Performance","Motor Symptoms","2026-06-11",{"date":70,"type":41},"2026-06-17",{"date":72,"type":22},"2026-07-01",{"date":74,"type":22},"2028-04-01",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100631695","human-clinical-trial-evaluating-the-blood-glucose-regulating-effects-of-momordica-charantia-peptides-100631695","NCT07504029","Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides","Inclusion Criteria:\n\n* Adults aged 30-65 years, both male and female.\n* Participants meeting any of the following criteria for prediabetes:\n\n  1. Fasting blood glucose 100-125 mg\u002FdL\n  2. HbA1c 5.7-6.4%\n  3. Previous clinical records indicating 2-hour OGTT glucose levels of 140-199 mg\u002FdL\n* Body mass index (BMI) between 24-35 kg\u002Fm², with waist circumference recorded (men ≥90 cm; women ≥80 cm).\n* Stable lifestyle (including diet, physical activity, and sleep habits) during the past three months.\n* No use of blood glucose-regulating supplements prior to or during the study.\n* Willingness to comply with study procedures and complete all required assessments.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus (HbA1c ≥6.5% or physician diagnosis).\n* Current use of antidiabetic medications (e.g., metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin).\n* Use of medications that may affect blood glucose levels, such as corticosteroids, antipsychotic drugs, or unstable thyroid medications.\n* Presence of severe hepatic, renal, cardiovascular diseases, active cancer, or gastrointestinal malabsorption disorders.\n* Pregnant or breastfeeding women, or those planning to become pregnant.\n* Body weight change exceeding ±5% within the past three months, or currently following a weight-loss program or special diet.\n* History of alcohol abuse or substance misuse.\n* Individuals engaged in night shift or rotating shift work.\n* Known allergy to any component of the study product.\n* Participation in another clinical trial within the past 1 month, or antibiotic use within the past 8 weeks (if gut microbiota analysis is involved).\n* Individuals who are students currently taught by Associate Professor You-Cheng Shen or Dr. Jing-Bin Lin, or laboratory staff, assistants, or employees with a supervisory or subordinate relationship with the investigators.","30 Years",{"count":84,"type":22},12,[25],"Prediabetes is a metabolic condition characterized by elevated blood glucose levels that are higher than normal but below the diagnostic threshold for diabetes. Early intervention to improve glycemic control may help delay the progression to type 2 diabetes. Momordica charantia (bitter melon) peptides have been reported to possess potential glucose-regulating effects.\n\nThis study aims to evaluate the effects of BmpP® bitter melon peptide supplementation on glycemic control in adults with prediabetes. This study is designed as a 12-week single-arm, open-label clinical trial. Approximately 12 adults aged 30-65 years with prediabetes will be recruited. Participants will consume bitter melon peptide capsules three times daily before meals for 12 weeks.\n\nPrimary outcomes include fasting blood glucose, postprandial glucose response, and HbA1c levels. The findings of this study may provide preliminary evidence regarding the potential role of bitter melon peptides in blood glucose regulation.",[88],"People With Prediabetic","RECRUITING","2026-03-25",{"date":92,"type":41},"2026-03-31",{"date":94,"type":41},"2026-03-13",{"date":96,"type":22},"2026-07-31",{"name":47,"class":48},1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100627046","the-effect-of-acupuncture-on-pulmonary-function-recovery-following-lung-resection-100627046","NCT07443540","The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection","The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection: A Clinical Trial","Inclusion Criteria:\n\n\\- Patients aged between 18 and 65 years.\n\nDiagnosed with a single pulmonary lesion (e.g., solitary pulmonary nodule or adenocarcinoma in situ).\n\nScheduled to undergo elective wedge resection for the lung lesion.\n\nExclusion Criteria:\n\n* History of prior lung resection.\n\nMedical history of asthma or pulmonary tuberculosis.\n\nHistory of pneumothorax prior to the current surgery.\n\nExpectation to receive rehabilitation therapies other than the standard protocol-defined incentive spirometry during the study period.\n\nPresence of other major systemic diseases (e.g., severe cardiovascular, renal, or hepatic impairment) that, in the investigator's opinion, render the patient unsuitable for trial participation.",{"count":107,"type":22},56,[25],"Background and Purpose:\n\nLung resection surgery is the standard treatment for early-stage lung adenocarcinoma, but it often leads to reduced lung volume and postoperative pain, which can hinder pulmonary recovery. While standard rehabilitation includes breathing exercises (incentive spirometry) and pain management, additional strategies are needed to enhance recovery. Acupuncture has shown benefits in managing respiratory diseases like COPD and reducing surgical pain, but its specific effectiveness in rehabilitation after lung resection has not yet been established. This study aims to evaluate whether adding acupuncture to standard postoperative care can further improve lung function and recovery.\n\nStudy Design and Methods:\n\nThis is a randomized controlled clinical trial. Participants who have undergone lung resection will be assigned to one of two groups:\n\nControl Group: Receives standard rehabilitation (lung volume training with incentive spirometry).\n\nIntervention Group: Receives standard rehabilitation plus acupuncture therapy.\n\nEvaluation:\n\nOne week after surgery, researchers will perform pulmonary function tests on all participants. The study will compare the two groups primarily based on improvements in lung function. Secondary outcomes, including pain levels and quality of life, will also be assessed to determine the overall benefit and safety of integrating acupuncture into postoperative recovery.",[111],"Lung Nodules",[113,114],"Lung nodules","acupuncture","2026-02-25",{"date":117,"type":41},"2026-03-02",{"date":119,"type":22},"2026-04-01",{"date":121,"type":22},"2027-01-30",{"name":47,"class":48},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":57,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100483277","formatting-the-risk-prediction-models-for-never-smoking-lung-cancer-100483277","NCT05572944","Formatting the Risk Prediction Models for Never-Smoking Lung Cancer","Validation and Optimization of Multidimensional Modelling for Never Smoking Lung Cancer Risk Prediction by Multicenter Prospective Study","FORMOSA","Inclusion Criteria:\n\n1. Age 50-80 years old\n2. First-degree relatives of lung cancer patients\n\n   * aged more than 50 - 80 years old\n   * or older than the age at diagnosis of the youngest lung cancer the proband in the family if they are less than 50 years old\n\nExclusion Criteria:\n\n1. Previous history of lung cancer\n2. Another malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years\n3. An inability to tolerate transthoracic procedures or thoracotomy\n4. Chest CT examination was performed within 18 months\n5. Hemoptysis of unknown etiology within one month\n6. Body weight loss of more than 6 kg within one year without an evident cause\n7. A known pregnancy","20 Years",{"count":133,"type":22},10000,"OBSERVATIONAL","Lung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patients are smokers in western countries the low-dose computed tomography screening focuses on the smoking population It is quite different in South-East Asia particularly in Taiwan that 53% of Taiwan lung cancer are never-smokers and the etiology and the underlying mechanisms are still unknown. The preliminary results of prospective TALENT study indicated that family history plays a key role in tumorigenesis of Taiwan lung cancers but several important variables such as air pollution, biomarkers, radiomics analysis are not available limits the accuracy of lung cancer identification. Hence, it is critical to integrate most of factors involved in lung cancer formation into a multidimensional lung cancer prediction model which could benefit never-smoker lung cancers in Taiwan and East Asia even in the western countries. The investigators initiate a clinical study to validate the multidimensional lung cancer prediction model for never-smoking population by multicenter prospective study.",[137],"Lung Cancer",[139,140,141],"Lung cancer","Low-dose computed tomography","Machine learning","2026-02-12",{"date":144,"type":41},"2026-02-17",{"date":146,"type":41},"2022-12-15",{"date":148,"type":22},"2029-12-31",{"name":47,"class":48},7,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":134,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100482088","development-and-clinical-validation-of-early-stage-lung-cancer-prognostic-kit-100482088","NCT05557474","Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit","Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit and Immunotherapy Companion Diagnostic Laboratory Developed Tests","Inclusion Criteria:\n\n* Willing to sign and provide subject consent.\n* Male or female of age 20 or older.\n* Patients diagnosed with lung adenocarcinoma by tumor pathology.\n* Lung cancer with the pathological stage of IA\u002FIB\u002FII\u002FIIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition).\n* Complete tumor resection (R0 resection).\n* The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping.\n* Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.).\n\nExclusion Criteria:\n\n* Not primary lung cancer patients.\n* Lung cancer patients whose pathological stage is not IA\u002FIB\u002FII\u002FIIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery.\n* Patients with uncontrolled malignant tumors other than lung cancer.\n* Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator )\n* Pregnant women.\n* Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.",{"count":159,"type":22},236,"5 Years","Lung cancer is the leading cause of cancer mortality worldwide in spite of the advanced progresses in medication and low-dose CT screening. The early-stage lung cancer accounts for less than 50% of newly diagnosed lung cancer in Taiwan, even in stage IB patients proximately 30% still suffer from recurrence and metastasis.\n\nThe International Cancer Moonshot Project recently established the first comprehensive proteogenomics profiling of early-stage lung cancer patients in East Asia, revealing a proteomics-informed classification to identify a new \"late like\" subtype, which can identify a subgroup of early-stage patients with worse clinicopathological features (Cell, Cover story, 2020). This study has been featured in prestigious journals (Nat Rev Clin Oncol; Cancer Discov, 2020) and led to two provisional US patents. In this proposal, taking the discovery from the Cancer Moonshot multiomics database, the investigators aim to translate these findings into clinical utilities. Two subprojects are proposed. (1) Validation of \"late-like\" protein markers for identifying high-risk early-stage lung cancer: Two IVD kits will be developed, including high-risk early-stage lung cancer IHC prediction kit for tumor staining and high-risk early lung cancer ELISA prediction kit for noninvasive diagnosis. (2) Conducting a prospective clinical trial to evaluate the accuracy of high-risk early-stage lung cancer IHC prediction kit and high-risk early-stage lung cancer ELISA prediction kit.",[137,163,164],"Surgery","Recurrence",[137,166,167,168,164],"Immunohistochemistry","Enzyme-linked Immunosorbent Assay","Laboratory developed tests",{"date":144,"type":41},{"date":171,"type":41},"2021-10-01",{"date":173,"type":22},"2028-12-31",{"name":47,"class":48},2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100622425","lung-cancer-screening-in-population-who-had-never-smoked-100622425","NCT07383454","Lung Cancer Screening in Population Who Had Never Smoked","Lung Cancer Screening in Population Who Had Never Smoked and the Validation of Lung Cancer Risk Prediction Model","Inclusion Criteria:\n\n1. Individuals with no history of smoking.\n2. Aged 40 to 80 years.\n3. Willing to provide written informed consent and complete questionnaire assessments.\n4. After undergoing examinations, willing to provide relevant biological information, including but not limited to: blood samples, urine samples, pulmonary function test results, imaging data, and tissue specimens obtained from invasive biopsies or surgical procedures (if applicable).\n\nExclusion Criteria:\n\n1. History of lung cancer, or a diagnosis of any malignancy other than skin cancer or cervical carcinoma in situ within the past five years.\n2. Undergoing chest computed tomography (CT) scans within the past 18 months.\n3. Unexplained hemoptysis within the past one month.\n4. Unexplained weight loss exceeding 6 kilograms within the past one year.\n5. Pregnancy.",{"count":184,"type":22},2500,[25],"Study design: prospective, single arm.\n\nObjectives: survey lung cancer detection rate of low-dose computed tomography (LDCT) screening in individuals who had never smoked.\n\nParticipants will undergo questionnaires, and collecting specimens including blood, urine, and medical informations including results of pulmonary function tests, and LDCT screening upon inclusion. The participants will be followed up according to current standards of clinical practice.",[188,189,190,191],"Lung Cancer (Diagnosis)","Non-Small Cell Lung Cancer","Small Cell Carcinoma of Lung","Screening Strategy",[193,194,195,139,196],"Low dose computed tomography (LDCT)","Lung cancer in individuals who had never smoked (LCINS)","Lung cancer risk prediction model (LCRPM)","Non-small cell lung cancer (NSCLC)","2026-01-26",{"date":199,"type":41},"2026-02-03",{"date":201,"type":22},"2026-02-01",{"date":203,"type":22},"2034-12",{"name":47,"class":48},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":98},"100590627","effects-of-probiotics-on-symptoms-of-constipation-in-adults-with-functional-constipation-100590627","NCT06969872","Effects of Probiotics on Symptoms of Constipation in Adults With Functional Constipation","The Effects of ABKefir on Functional Constipation in Subjects: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* male or female\n* aged 18-75 years old\n* fulfill Rome IV criteria for functional constipation\n* have not participated in similar research in the past three months\n\nExclusion Criteria:\n\n* Personal or family history of colon cancer, celiac disease, and inflammatory bowel disease\n* Irritable bowel syndrome diagnosed during colonoscopy\n* Those who are pregnant recently (including men and women), or are pregnant or breastfeeding women.\n* Taking antidepressants, anti-anxiety drugs and other psychotropic drugs.\n* Long-term medication is required to improve constipation\n* Those diagnosed with myocardial infarction, cerebral infarction, malignant tumor and\u002For other serious diseases are not suitable for participating in the study.\n* Allergic symptoms to probiotics or any ingredients\n* Having a history of serious mental illness\n* Drug-related crimes or alcohol problems\n* Have recently traveled to areas where parasitic diseases are prevalent.","75 Years",{"count":214,"type":22},165,[25],"The purpose of this study was to evaluate the efficacy of 1 capsules of ABKefir per day on symptoms of constipation in subjects with functional constipation by clinical trial.",[218],"Functional Constipation (FC)","2025-12-29",{"date":221,"type":41},"2026-01-02",{"date":223,"type":41},"2024-12-27",{"date":225,"type":22},"2026-09-30",{"name":47,"class":48},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":98},"100614661","evaluation-of-vedan-rt-90-resistant-cassava-starch-for-glycemic-control-and-prebiotic-fiber-development-in-a-human-trial-100614661","NCT07282496","Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial","Inclusion Criteria:\n\n* Subjects aged 18-65 years.\n* Healthy subjects (BMI between 18.5-24.9 kg\u002Fm² for women and men).\n* Subjects must be able to maintain a stable diet (based on the Ministry of Health and Welfare's daily dietary guidelines, with a tolerance of ± 10-15%) and physical activity (based on the World Health Organization's recommendations of 150-300 minutes of moderate-intensity exercise per week, or equivalent physical activity, with a tolerance of ± 20%) during the trial period.\n* Subjects must understand the trial procedures and potential risks and benefits described in the consent form and be able to sign the consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Subjects with endocrine abnormalities, major organ disease, or mental illness (as determined by a physician).\n* Subjects found to be intolerant to the test sample during the trial.\n* Subjects who develop a disease or take medications or health supplements that could affect the results of the trial during the trial period. (e.g., hypoglycemic (lipid)-lowering medications, probiotics, high-dose dietary fiber supplements, fish oil, or supplements high in polyunsaturated fatty acids).\n* Chronic gastrointestinal diseases (e.g., diverticular disease, irritable bowel syndrome, or other intestinal diseases that may cause constipation).\n* Use of antibiotics within the past three months.",{"count":234,"type":22},115,[25],"This study aims to investigate the effects of RT-90 resistant cassava starch on glycemic control using a human dietary trial and to evaluate its potential as a prebiotic fiber supplement. This study will assess the efficacy of RT-90 resistant cassava starch in improving glycemic control, body composition, and gut microbiome in healthy individuals.",[238,239,240,241],"Resistant Starch","Tapioca Starch","Prebiotic Fiber","Blood Sugar","2025-12-01",{"date":244,"type":41},"2025-12-15",{"date":246,"type":22},"2025-12-20",{"date":248,"type":22},"2026-10-31",{"name":47,"class":48},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":57,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":268,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":98},"100612359","mouthwash-temperature-and-oral-mucositis-in-head-and-neck-radiotherapy-100612359","NCT07252557","Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy","Effectiveness of Different Mouthwash Temperatures on Oral Mucositis Pain and Patient Comfort During Radiotherapy for Head and Neck Cancer: A Randomized Controlled Trial","CoolRinseHNC","Inclusion Criteria:\n\n* Histologically confirmed head and neck cancer (HNC) receiving radiotherapy for the first time, with or without concurrent chemotherapy.\n* Conscious, communicative, and able to perform the rinsing procedure and complete questionnaires.\n* Provided written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Non-HNC diagnoses or radiotherapy to sites outside the oral\u002Foropharyngeal region.\n* Cognitive impairment or inability to complete the rinsing protocol.",{"count":259,"type":22},200,[25],"This single-center randomized controlled trial evaluates the effects of cold (15-20°C) versus room-temperature (30-35°C) water gargling on oral mucositis severity, pain, and comfort in patients with head and neck cancer undergoing radiotherapy. Participants will rinse their mouth four times daily for 30-60 seconds over a 6-week radiotherapy course, with follow-up for two additional weeks. The study hypothesizes that cold-water rinsing can reduce the severity of radiation-induced oral mucositis (RTOM) and pain, improve oral comfort, and minimize treatment interruptions.",[263,264,265,266,267],"Head and Neck Cancer (H&Amp;Amp;N)","Radiation-induced Oral Mucositis","Supportive Care","Nursing Interventions","Radiotherapy Side Effects",[269,270,271,272,265,273,274,275],"Head and Neck Cancer","Radiation-Induced Oral Mucositis","Water Temperature","Cold Water Rinse","Pain Management","Radiotherapy","Nursing Intervention","2025-11-24",{"date":278,"type":41},"2025-11-26",{"date":280,"type":22},"2026-01-01",{"date":282,"type":22},"2027-03-31",{"name":47,"class":48},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":98},"100599841","effects-of-a-glp-1-formula-drink-on-gut-microbiota-and-glycemic-control-in-prediabetic-individuals-100599841","NCT07089732","Effects of a GLP-1 Formula Drink on Gut Microbiota and Glycemic Control in Prediabetic Individuals","Evaluation of the Effects of GLP-1 Formula Liquid Drink on Gut Microbiota Modulation and Blood Glucose Regulation in Prediabetic Populations","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Clinically diagnosed with prediabetes (fasting plasma glucose: 100-125 mg\u002FdL or HbA1c: 5.7-6.4%) or with a body mass index (BMI) of 25-34.9 kg\u002Fm², male or female.\n* Have not participated in similar clinical studies within the past three months.\n* Able to comprehend the informed consent form, including the study procedures, potential risks, and benefits, and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with autoimmune diseases or cancer.\n* Diagnosed with gastrointestinal chronic diseases such as irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, celiac disease, bowel control disorders, fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, ulcerative colitis, lactose intolerance, or chronic diarrhea.\n* History of gastrointestinal surgery.\n* Planning pregnancy in the near future (including male partners), currently pregnant, or breastfeeding women.\n* Known allergy or hypersensitivity to probiotics or any of the study product ingredients.\n* History of major psychiatric disorders.\n* History of substance abuse or alcohol dependency.","70 Years",{"count":293,"type":22},100,[25],"A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.",[297,298],"Obesity","Prediabetes","2025-07-25",{"date":301,"type":41},"2025-07-28",{"date":303,"type":22},"2025-08-08",{"date":305,"type":22},"2026-06-30",{"name":47,"class":48},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":175},"100596651","specimen-and-clinical-data-collection-plan-for-ldct-screening-participants-100596651","NCT07048236","Specimen and Clinical Data Collection Plan for LDCT Screening Participants","Inclusion Criteria:\n\nPrevious heavy smokers\n\nAccording to The Lung Cancer Early Detection Program in Taiwan:\n\nAdults aged 50 to 74 years with a smoking history of at least 20 pack-years, who are either current smokers or have quit smoking within the past 15 years. Current smokers must agree to participate in a smoking cessation program.\n\nFirst-degree relatives of lung cancer patients\n\nAccording to The Lung Cancer Early Detection Program in Taiwan:\n\nMen aged 45 to 74 years and women aged 40 to 74 years who have a biological parent, child, or sibling diagnosed with lung cancer. Individuals who currently smoke must agree to participate in a smoking cessation program.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. History of chest computed tomography (including low-dose CT) within the past 12 months.\n3. Previous diagnosis of lung cancer\n4. Inability to undergo thoracic biopsy or surgery\n5. Inability to complete the scan procedure, such as due to being unable to hold their breath.\n6. Unexplained hemoptysis within the past month\n7. Chest X-ray within the past month showing a clearly suspicious lung lesion\n8. Unexplained weight loss exceeding 6 kilograms within the past year","74 Years",{"count":315,"type":22},12000,"Lung cancer remains the leading cause of cancer-related mortality in Taiwan and globally, with increasing incidence and the highest healthcare cost burden among cancers in Taiwan. Despite the widespread use of low-dose computed tomography (LDCT) for screening smokers, over half of lung cancer cases in Taiwan occur in never-smokers, highlighting the need for improved risk stratification. Current national LDCT screening programs do not collect comprehensive risk-related data, limiting their predictive accuracy. This project proposes a five-year, multi-center initiative to establish an integrated biospecimen and clinical data collection system. In its first year, a feasibility pilot will be conducted, followed by recruitment of 12,000 participants. Data collection will include biospecimens (blood, urine, tissue), genomic and proteomic analyses, imaging, and detailed questionnaires covering lifestyle, environmental, and occupational exposures. The project will also develop and validate lung cancer prediction models incorporating epidemiologic, biomarker, air pollution, and imaging data. A Common Data Model (CDM) will be implemented to ensure cross-institutional data standardization and support future international collaboration.",[137,318,319],"Smoking","Family Relations",[321,140,322,318,323,324,325],"lung cancer","Lung cancer family history","proteomic","genomic","Lung cancer risk questionnaire","2025-07-15",{"date":328,"type":41},"2025-07-18",{"date":330,"type":22},"2025-07-17",{"date":332,"type":22},"2034-12-31",{"name":47,"class":48},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":341,"minAge":131,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":98},"100521433","effect-of-lactobacillus-johnsonii-or-white-pomegranate-extract-on-the-vaginal-health-100521433","NCT06069531","Effect of Lactobacillus Johnsonii or White Pomegranate Extract on the Vaginal Health","Effect of Oral Probiotic Heat-killed Lactobacillus Johnsonii TCI250 or White Pomegranate Extract on the Vaginal Flora","Inclusion Criteria:\n\n1. Females aged 20-45\n2. Nugent score ≥ 4\n3. Menstrual cycle of 28-60 days\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Antibiotic usage\n3. Other reproductive-related inflammatory diseases (e.g., candidiasis, gonorrhea, chlamydia infection)\n4. Allergy to probiotics or White Pomegranate-related components","FEMALE","45 Years",{"count":344,"type":22},150,[25],"The goal of this clinical trial is to explore the effect of Lactobacillus johnsonii and white pomegranate extract on female bacterial status, it aims to answer are:\n\n* Evaluate Lactobacillus johnsonii TCI250 probiotics or white pomegranate extract in regulating female vaginal bacteria and improving vaginal health.\n* Evaluate Lactobacillus johnsonii TCI250 probiotics or white pomegranate extract in regulating inflammation.\n\nParticipants will be randomly assigned to placebo (n = 50), probiotic heat-killed Lactobacillus johnsonii TCI250 group (n = 50) and white pomegranate extract group (n = 50) for 8 weeks. Researchers will compare the vaginal flora and inflammation.",[348,349],"Vaginitis Bacterial","Inflammation, Ear",[351,352,353,354,355],"Bacterial Vaginitis","Probiotics","white pomegranate extract","Inflammation","Vaginal flora","2025-05-12",{"date":358,"type":41},"2025-05-14",{"date":360,"type":41},"2022-04-04",{"date":362,"type":22},"2025-12-31",{"name":47,"class":48},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":371,"minAge":372,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":381,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":98},"100589582","the-efficiency-of-a-new-sperm-wash-device-for-intrauterine-insemination-in-couples-with-infertility-100589582","NCT06956287","The Efficiency of a New Sperm-Wash Device for Intrauterine Insemination in Couples With Infertility","IUI","Inclusion Criteria:\n\n* Males aged between 25 to 50 years.\n* Part of a couple diagnosed with infertility.\n* Undergoing intrauterine insemination (IUI) treatment.\n* Sperm concentration \\>15 million\u002FmL, progressive motility \\>32%, and total motile sperm count \\>40 million after wash.\n* Willingness of both partners to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Known female infertility factors requiring assisted reproductive technologies beyond IUI.\n* Severe male factor infertility (e.g., oligoasthenoteratozoospermia).\n* Use of donor sperm or oocyte.\n* Chronic illness or medications affecting sperm quality.\n* Prior participation in another clinical trial within the past 3 months.","MALE","25 Years","50 Years",{"count":375,"type":22},120,[25],"This study evaluates the effectiveness of a novel sperm-wash device designed to improve outcomes in intrauterine insemination (IUI) for couples with infertility. Traditional sperm preparation methods, such as density gradient centrifugation (DGC), are associated with elevated reactive oxygen species (ROS) levels and increased sperm DNA fragmentation, potentially compromising pregnancy rates. The new device aims to reduce these adverse effects by minimizing oxidative stress and preserving sperm DNA integrity.\n\nIn this prospective, randomized controlled trial, 120 couples will be allocated to either the intervention group using the new device or the control group using DGC. The primary outcome is the clinical pregnancy rate, while secondary outcomes include sperm DNA fragmentation. The study hypothesizes that the novel device will result in higher pregnancy rates and reduced DNA fragmentation compared to DGC. These findings may support its use as a more physiological approach to sperm preparation in fertility treatment.",[379,380],"Infertility","Male Infertility",[379,382,383,384,385,386,387,388],"intrauterine insemination (IUI)","artificial insemination husband","sperm selection","sperm DNA fragmentation","oxidative stress","fertility treatment","male infertility","2025-05-05",{"date":391,"type":41},"2025-05-08",{"date":393,"type":41},"2025-04-24",{"date":395,"type":22},"2026-12-31",{"name":47,"class":48},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":16,"sex":341,"minAge":131,"maxAge":19,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":98},"100581324","difference-of-tear-ferning-between-women-with-and-without-menopausal-100581324","NCT06848829","Difference of Tear Ferning Between Women with and Without Menopausal.","Difference of Tear Ferning Between Pre-and Post-menopausal Women and Between Post-menopausal Women with or Without Hormone Replacement Therapy (HRT)","Inclusion Criteria:\n\n* Aged between 20 and 65 years\n\nExclusion Criteria:\n\n* No evident ocular diseases such as cornea, cataracts, vitreous degeneration, glaucoma, and retinopathy.\n* Belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)",{"count":405,"type":22},90,[25],"Application of tear ferning test for clinical dry eye diagnosis and menopause",[409],"Dry Eye Syndromes",[411,412,413],"Dry Eye diagnosis","Tear ferning","menopause","2025-02-21",{"date":416,"type":41},"2025-02-27",{"date":418,"type":41},"2024-10-01",{"date":420,"type":22},"2025-10-01",{"name":47,"class":48},{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":437,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":452,"locationsCount":98},"100580169","application-of-intelligent-care-systems-in-radiation-therapy-enhancing-patient-safety-and-reducing-anxiety-through-system-optimization-and-real-time-blood-data-monitoring-100580169","NCT06833801","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization and Real-Time Blood Data Monitoring","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization, Enhanced Education Strategies, and Real-Time Blood Data Monitoring","ICS-RT","Inclusion Criteria:\n\n* Patients undergoing radiation therapy combined with chemotherapy.\n* Age ≥ 18 years.\n* Ability to understand and comply with the study protocol.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or intellectual disability, affecting their ability to understand or follow study procedures.\n* Patients unwilling to complete study questionnaires.\n* Any mental health condition (e.g., major depressive disorder, severe anxiety disorder) that could interfere with participation.\n* Patients with conditions requiring immediate intervention that would make study participation impractical.",{"count":293,"type":22},[25],"This study aims to evaluate the impact of an intelligent care system on radiation therapy patients, focusing on real-time blood data monitoring, optimized patient education, and internal alert systems. The goal is to enhance patient safety, improve treatment adherence, and reduce anxiety by integrating an alert function into the hospital's existing system.\n\nKey interventions include:\n\nReal-time blood monitoring alerts: Healthcare providers will receive automatic notifications of abnormal blood test results to ensure timely intervention.\n\nOptimized patient education materials: Clearer guidance will help patients proactively communicate blood test needs and manage their health during radiation therapy.\n\nInternal reminders: Visual signs and alerts in treatment areas will reinforce patient awareness and engagement.\n\nThe study will compare patients receiving these interventions with those under standard care, assessing treatment compliance, anxiety levels, and clinical outcomes over a 12-month period.",[434,435,34,436],"Radiation Therapy","Chemoradiotherapy","Adherence",[434,438,439,440,441,442,443,444,445,446],"Intelligent Care System","Real-Time Blood Data Monitoring","Patient Safety","Oncology Treatment Compliance","Cancer Treatment Anxiety","Clinical Decision Support System","Health Education in Radiation Oncology","Automated Blood Test Alerts","Supportive Care in Cancer Patients","2025-02-18",{"date":449,"type":41},"2025-02-20",{"date":449,"type":22},{"date":362,"type":22},{"name":47,"class":48},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":19,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":98},"100558683","effect-of-probiotics-on-regulating-gut-health-and-blood-lipid-in-adults-100558683","NCT06554314","Effect of Probiotics on Regulating Gut Health and Blood Lipid in Adults","Effect of Probiotics on Regulating Gut Health and Blood Lipid in Overweight and Obese Adults","Inclusion Criteria:\n\n* male or female participants\n* aged 20-65 years old\n* body mass index in 25-27 kg\u002Fm2 or body fat \\> 25% for men and \\> 30% for women\n\nExclusion Criteria:\n\n* cancer, chronic heart disease, use drugs which pharmacological effects may affect immunity having systemic infections\n* using probiotics.",{"count":461,"type":22},50,[25],"The purpose of this study was to evaluate the efficacy of 1 capsules (300 mg per capsule) of Nutrarex Probiotic Capsules per day in regulating gut health and blood lipid in adults by clinical trial.",[297],"2024-08-12",{"date":467,"type":41},"2024-08-15",{"date":469,"type":41},"2024-05-17",{"date":471,"type":22},"2025-05-31",{"name":47,"class":48},{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":17,"minAge":373,"maxAge":57,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":493,"locationsCount":98},"100519235","causal-effect-of-coenzyme-q10-nutrition-and-cognitive-dysfunction-in-the-metabolic-storm-hyperglycemia-and-sarcopenia-and-brain-derived-neurotrophic-factor-100519235","NCT06040905","Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor","Inclusion Criteria:\n\n* Clinical diagnosis of mild cognitive impairment (MCI).\n* Clinical diagnosis of Alzheimer's Disease.\n* MCI and AD patients with hyperglycemia ( Fasting glucose \\>=100 mg\u002FdL).\n* MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).\n* Must be able to swallow tablets.\n\nExclusion Criteria:\n\n* Cancer patients.\n* Severe heart, lung, liver, and kidney diseases.\n* Severe disability or aphasia.\n* Malnutrition (body weight changes \\> 5% within one month).\n* Using coenzyme Q10 supplements.\n* Warfarin therapy.",{"count":293,"type":22},[25],"The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg\u002Fb.i.d, 300 mg\u002Fd, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.",[483,484,485,486],"Mild Cognitive Impairment","Alzheimer Disease","Hyperglycemia","Pre-sarcopenia","2024-02-05",{"date":489,"type":41},"2024-02-07",{"date":491,"type":41},"2023-12-26",{"date":96,"type":22},{"name":47,"class":48},""]